

- タリックスステント.追加留置により止血し得た膵頭体部癌の1例第98回日本消化器病学会九州支部例会2011.11.18・19 長崎
238. 中村聡明. 膵癌術前化学放射線治療60Gy後の消化管障害. 第24回日本放射線腫瘍学会2011.11.19, 神戸
239. Shuichi Mitsunaga, Masafumi Ikeda, Atsushi Ochiai. Neural invasion induces cachexia and pain in pancreatic cancer. 6th Cachexia Conference. December 8-10, 2011 Milan.
240. Haba S, Hara K, Mizuno N, Hijioka S, Imaoka H, Niwa Y, Tajika M, Kondo S, Tanaka T, Shimizu Y, Yatabe Y, Hosoda W, Yamao K: Diagnostic Ability of Endoscopic Ultrasound-guided Fine Needle Aspiration for Pancreatic Solid Lesions: A Large Single . APDW 2011,2011.(Singapore)
241. 古瀬純司: 膵・胆道癌化学療法. 最新の知見. ランチョンセミナー5. 第49回日本癌治療学会学術集会. 2011.10.27, 名古屋市
242. 古瀬純司: 膵がん第Ⅲ相試験のエンドポイント. Debate Session 2. 抗悪性腫瘍薬第Ⅲ相試験のエンドポイント. 第49回日本癌治療学会学術集会. 2011.10.27, 名古屋市
243. 奥坂拓志. (ランチョンセミナー25: 大鵬) 膵癌に対する化学療法. 最近の話題から第49回日本癌治療学会学術集会. 2011.10.27-29, 名古屋市
244. 大川伸一、井岡達也、池田公史、上野秀樹、朴成和、水元一博、船越顕博、佐藤温、奥坂拓志、GEST study group: 進行膵癌に対するGEM.TS-1.GEM+TS-1の第Ⅲ相試験(GEST). 第49回日本癌治療学会、2011.10.28、名古屋国際会議場、名古屋
245. 須藤研太郎、山口武人、中村和貴、原太郎、傳田忠道、廣中秀一、相馬寧、幡野和男、石原武、多田素久、三方林太郎、太和田勝之、趙明浩、貝沼修、山本宏. 局所進行膵癌に対する集学的治療の検討. 第49回日本癌治療学会、2011.10.27, 名古屋.
246. 須藤研太郎、山口武人、中村和貴、原太郎、傳田忠道、廣中秀一、北川善康、中村奈海、幡野和男、多田素久、三方林太郎、太和田勝之、石原武. 進行膵癌に対する化学放射線療法におけるメタリックスステントの安全性に関する検討. 第49回日本癌治療学会、2011.10.27日、名古屋.
247. 松本俊彦、西出憲史、梶原猛史、浅木彰則、壺内栄治、仁科智裕、堀伸一郎、灘野成人、谷水正人、井口東郎. 胆道出血に対し内視鏡的金属ステント留置術にて止血しえた切除不能膵癌の1例. 第49回日本癌治療学会総会2011.10.27-29, 名古屋.
248. 伊藤芳紀. シンポジウム「放射線治療: その治療成績と課題」膵がん. 第49回日本癌治療学会学術集会. 2011.10.29, 名古屋.
249. 桑原明子、仲地耕平、奥山浩之、高橋秀明、大野泉、清水怜、光永修一、池田公史. 進行膵癌に対する2次化学療法としてのゲムシタビンの有効性・安全性 第49回日本癌治療学会学術集会 2011.10.27-10.29 名古屋市
250. 福富晃、奥坂拓志、池田公史、大谷悟、柴山和弘、田窪孝、Jennifer Gansert. 転移性膵癌に対するゲムシタビン+Ganitumab(AMG 479)併用第1b相試験 第49回日本癌治療学会学術集会2011.10.27-10.29 名古屋市
251. 大川伸一、井岡達也、池田公史、上野秀樹、朴成和、水元一博、船越顕博、佐藤温、奥坂拓志. 進行膵癌に対するGEM.TS-1+TS-1の第Ⅲ相試験(GEST) 第49回日本癌治療学会学術集会2011.10.27-10.29 名古屋市
252. 柴本薫、福富晃、安井博史、小野澤祐輔、山崎健太郎、町田望、戸高明子、對馬隆浩、谷口浩也、朴成和、膵癌化学療法後のBest Supportive Careの現状、第49回日本癌治療学会、2011、名古屋
253. 須藤研太郎、山口武人、中村和貴、原太郎、廣中秀一、中村奈海、傳田忠道、北川善康、三梨桂子、多田素久、三方林太郎、太和田勝之、石原武、趙明浩、貝沼修、山本宏. 切除不能局所進行膵癌に対する集学的治療の検討. 第53回日本消化器病学会大会

- (JDDW2011).2011.10.21,福岡.
254. 新名雄介、五十嵐久人、李 倫学、藤森 尚、大野隆真、肱岡真之、下川雄三、内田匡彦、中村太一、木村寿成、高柳涼一、伊藤鉄英. 切除不能膵癌による悪性十二指腸狭窄に対する金属ステント留置の有用性. JDDW2011 第 19 回日本消化器病関連学会週間. (第 82 日本消化器内視鏡学会総会). 2011.10.20-23, 福岡
255. 松本俊彦、浅木彰則、梶原猛史、壺内栄治、仁科智裕、堀伸一郎、灘野成人、井口東郎. 当院における切除不能膵癌の長期生存要因の検討. 第 53 回日本消化器病学会大会 2011.10.20-23, 福岡.
256. 奥坂拓志. (パネルディスカッション 12 切除不能進行消化器がんに対する治療選択) 切除不能進行消化器がんに対する治療選択. 消 PD12-8) 第 53 回日本消化器関連学会週間(JDDW2011). 2011.10.20-21, 福岡市
257. 川口義明, 小川真実, 内田哲史, 伊藤裕幸, 峯 徹哉. 膵疾患(慢性膵炎、膵癌)患者におけるアミノ酸代謝異常. 第 53 回日本消化器病学会. 2011.10
258. Furuse J. Role of adjuvant and neoadjuvant therapy. ISDS Main Session. Pancreatic neoplasms: up-date 2011. International Surgical Week. 2011.8.31, Yokohama
259. 佐田尚宏、小泉 大、兼田 裕司、志村 国彦、笹沼 英紀、佐久間 康成、俵藤 正信、安田 是和. 当科における(幽門輪温存)膵頭十二指腸切除術術者へのロードマップと Quality control 第 38 回日本膵切研究会 シンポジウム. 2011.8.26, 久留米
260. 原太郎, 山口武人, 石原武. 抗腫瘍療法時代の進行膵癌に対する胆管ステントイング -First stent の選択: CMS か UMS か?-. 第 81 回日本消化器内視鏡学会総会, 2011.8.17, 名古屋.
261. 安藤知子、亀田亮、上野誠、大川伸一、小林智: 当院における悪性胃十二指腸狭窄に対する経内視鏡的十二指腸ステントの使用成績. 第 81 回日本消化器内視鏡学会、2011.8.17、名古屋国際会議場、名古屋
262. 宮本敦史、池永雅一、安井昌義、辻江正徳、末田聖倫、山下公太郎、武岡奉均、宮崎道彦、平尾素宏、藤谷和正、三嶋秀行、中森正二、辻仲利政. 消化器外科緊急手術例における手術部位感染に関する検討. 第 47 回 日本腹部救急医学会総会, 2011.8.11 日, 福岡市
263. 土岐昌朗、山口康晴、倉田勇、村上隆夫、内田康仁、川越圭、田部井弘一、畑英行、蓮江智彦、比嘉晃二、田内優、中村健二、阿部展次、森秀明、大倉康男、杉山政則、石田均、古瀬純司、高橋信一: 膵癌のリスクファクターとしての糖尿病-糖尿患者における効率的な膵癌スクリーニングを目指して-. ワークショップ 1: 生活習と膵疾患. 第 42 回日本膵臓学会大会 2011.7.29, 弘前市
264. 柳本泰明、井岡達也、池田公史、大川伸一、杉森一哉、福富晃、馬場秀夫、山雄健次、上野秀樹、朴成和、水元一博、古瀬純司、羽鳥隆、船越顕博、山口武人、江川新一、佐藤温、大橋靖雄、田中雅夫、奥坂拓志: 進行膵癌に対する GEM.TS-1.GEM+TS-1 の第 3 相試験 (GEST) . 特別企画: 進行膵がん治療の新展開. 第 42 回日本膵臓学会大会 2011.7.29, 弘前市
265. 古瀬純司: 膵がん化学療法: 最新情報. コーヒーブレイク セミナー 2. 第 42 回日本膵臓学会大会. 2011.7.30, 弘前市
266. 奥坂拓志. (座長) 膵がん治療(7) 第 42 回日本膵臓学会大会. 2011.7.29-30, 弘前市
267. 山口智宏、近藤俊輔、森実千種、上野秀樹、奥坂拓志. (一般口演 O-98) パクリタキセル.カルボプラチン併用療法を施行した膵原発粘液性嚢胞腺癌の 1 例. 第 42 回日本膵臓学会大会. 2011.7.29-30, 弘前市
268. 柴 知史、森実千種、奥坂拓志、上野秀樹、池田公史、近藤俊輔、山口智宏、小菅智男、島田和明、平岡伸介. (一般口演 O-51) WHO 新分類を用いた膵内分泌腫瘍 100 例の検討. 第 42 回日本膵臓学会大会. 2011.7.29-30, 弘前市
269. 北川善康, 山口武人, 須藤研太郎, 中村和貴, 原太郎, 傳田忠道, 中村奈海, 廣中秀一,

- 三梨桂子,相馬寧,貝沼修,趙明浩,朴成進,山本宏.化学療法施行後根治切除を行い得た局所進行膵癌の1例.第42回日本膵臓学会大会,2011.7.29日,青森.
270. 須藤研太郎,山口武人,中村和貴,原太郎,傳田忠道,廣中秀一,多田素久,太和田勝之,三方林太郎,趙明浩,貝沼修,山本宏,幡野和男,石原武.局所進行膵癌に対する非切除治療の検討.第42回日本膵臓学会大会,2011.7.30日,青森.
271. 小林智,上野誠,大川伸一,亀田亮:膵癌診断・治療における OncoPDT-Pabc の有用性.第42回日本膵臓学会,2011.7.29、ホテルニューキャッスル、弘前
272. 山上裕樹、宮沢基樹、水野伸匡、奥坂拓志、福富晃、石井浩、大川伸一、古川正幸、真口宏介、池田公史、西尾和人、大橋靖雄、角田卓也:切除不能膵癌に対するペプチドワクチン療法—第II.Ⅲ相臨床試験:PEGASUS-PC試験について—.第42回日本膵臓学会、2011.7.29、ホテルニューキャッスル、弘前
273. 井口東郎.膵疾患診療における画像診断:PET-CTの位置づけ.第42回日本膵臓学会大会 ランチョンセミナー 2011.7.30,弘前.
274. 古川正幸、船越顕博.2型糖尿病に発症する膵癌の臨床的特徴.第42回日本膵臓学会大会.2011.07.29-2011.7.30,弘前
275. 光永修一、池田公史、仲地耕平、大野泉、清水怜、高橋秀明、奥山浩之、稲垣正俊、古瀬純司、落合淳志.進行膵がんにおいて、病状悪化を認める IL-6 高値群のうち IL-1 高値群は予後不良である (口演) 第42回日本膵臓学会大会.2011.7.29-7.30 青森
276. 酒井健司、光永修一、仲地耕平、清水怜、上野秀樹、森実千種、近藤俊輔、奥坂拓志、池田公史.肝転移を有する膵腺房細胞癌に対しゲムシタピン塩酸塩と S-1 併用療法を行った2例 (口演) 第42回日本膵臓学会大会.2011.7.29-7.30 青森
277. 高橋進一郎、小西大、木下敬弘、後藤田直人、加藤祐一郎、池田公史、仲地耕平、光永修一、大野泉、木下平. Borderline resectable 膵癌を対象とした臨床試験の必要性 (口演) 第42回日本膵臓学会大会.2011.7.29-7.30 青森
278. 小倉 健, 原 和生, 水野伸匡, 澤木 明, 山雄健次: EUS-FNA 検体における K-ras 遺伝子変異の有用性の検討. 第42回日本膵臓学会,2011.青森
279. Shuichi Mitsunaga, Masafumi Ikeda, Izumi Ohno, Satoshi Shimizu, Hideki Ueno, Chigusa Morizane, Shunsuke Kondo, Takuji Okusaka The degree of circulating CRP level predicts the results of GEM-monotherapy in patients with advanced pancreatic cancer. (ワークショップ) 第9回日本臨床腫瘍学会学術集会. 2011.07.21-7.23 横浜
280. Ikeda M, Ioka T, Ohkawa S, Yanagimoto H, Mizuno N, Boku N, Furuse J, Hatori T, Funakoshi A, Yamaguchi T, Egawa S, Sato A, Ohhashi Y, Tanaka M, Okusaka T: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. プレナリーセッション. 第9回日本臨床腫瘍学会学術集会. 2011.7.22, 横浜市
281. 奥坂拓志、池田公史. (ワークショップ座長) 胆膵癌化学療法の現状と問題点. 日本臨床腫瘍学会学術集会. 2011.7.21-23,横浜市
282. 奥坂拓志. 胆道・膵臓癌. 第18回日本臨床腫瘍学会教育セミナーB. 2011.7.23, 横浜市
283. Ueno H, Kouge T, Sakamoto Y, Saiura A, Ishii H., Okusaka T. (ワークショップ) Adjuvant therapy for resectable pancreatic cancer: to develop more effective treatment. (WS-5-6) 日本臨床腫瘍学会学術集会. 2011.7.21-23,横浜市
284. Kondo S, Ueno H, Morizane C, Koizumi F, Tamura K, Okusaka T. (一般口演) Long pentraxin 3 is associated with a poor prognosis in pancreatic carcinoma patients on gemcitabine based chemotherapy. (03-011) 日本臨床腫瘍学会学術集会. 2011.7.21-23,横浜市
285. Taniyama T, Morizane C, Ueno H, Kondo

- S, Yamaguchi T, Syoji H, Nakachi K, Ikeda M, Mitsunaga S, Kosuge T, Shimada K, Sakamoto Y, Esaki M, Nara S, Okusaka T. (一般口演 肝胆膵がん(2) 膵がん①) The treatment outcome of chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy. (03-008) 日本臨床腫瘍学会学術集会. 2011.7.21-23,横浜市
286. Shiba S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Kosuge T, Shimada K, Yamaguchi T, Hiraoka N. (一般口演 肝胆膵がん(3) 膵がん② その他) One hundred cases of pancreatic endocrine tumors: 20 years of experience at a single center. (03-013) 日本臨床腫瘍学会学術集会. 2011.7.21-23,横浜市
287. Mitsunaga S, Ikeda M, Oono I, Shimizu S, Ueno H, Morizane C, Kondo S, Okusaka T. (ワークショップ) The degree of circulating CRP level predicts the results of GEM-monotherapy in patients with advanced pancreatic cancer. (WS-5-3) 日本臨床腫瘍学会学術集会. 2011.7.21-23,横浜市
288. Terashima T, Morizane C, Kondo S, Ueno H, Ikeda M, Saito Y, Shimada Y, Kushima R, Hiraoka N, Kanai Y, Okusaka T. (一般口演) Extra-pulmonary neuroendocrine tumors: An institutional experience of 337 patients at the National Cancer Center Hospital in Japan. (02-103) 日本臨床腫瘍学会学術集会. 2011.7.21-23,横浜市
289. Otsuka T, Morizane C, Nara S, Okusaka T, Ueno H, Kondo S, Shimada K, Kosuge T, Hiraoka N. (一般口演) Gemcitabine monotherapy in patients with recurrent intraductal papillary mucinous carcinoma of the pancreas.(03-014) 日本臨床腫瘍学会学術集会. 2011.7.21-23,横浜市
290. 中村聡明. 膵癌の化学放射線療法. 第9回日本臨床腫瘍学会, 2011.7.22日,横浜
291. 須藤研太郎, 山口武人, 中村和貴, 傳田忠道, 原太郎, 廣中秀一, 相馬寧, 趙明浩, 貝沼修, 山本宏, 幡野和男, 太和田勝之, 多田素久, 三方林太郎, 石原武. 局所進行膵癌に対する集学的治療の検討. 第9回日本臨床腫瘍学会, 2011.7.22日,横浜.
292. 高橋進一郎, 木下平, 小西大, 後藤田直人, 加藤祐一郎, 木下敬弘, 池田公史. 切除可能膵癌と局所進行膵癌の資料成績から検討する浸潤性膵管癌の治療戦略. 第66回日本消化器外科学会総会. 2011.7.14 名古屋市
293. 杉本理恵, 奥村幸彦, 植田圭二郎, 古川正幸, 船越顕博. ラジオ波が著効した化学療法後の膵癌肝転移の1例. 第97回日本消化器病学会九州支部例会第91回日本消化器内視鏡学会九州支部例会 2011.06.24-2011.06.25 : 久留米
294. 脇岡真之, 岩尾梨沙, 李倫学, 内田匡彦, 新名雄介, 藤森尚, 中村太一, 大野隆真, 五十嵐久人, 伊藤鉄英, 高柳涼一. 局所進行膵癌に対してS-1併用放射線療法を施行した4症例の検討. 第41回九州膵研究会 2011.6.23 久留米
295. 植田圭二郎, 古川正幸, 奥村幸彦, 杉本理恵, 船越顕博, 在田修二, 熊谷穂積. 悪性胃十二指腸狭窄に対する十二指腸ステント留置の有用性 - 当院6症例における使用成績. 第97回日本消化器病学会九州支部例会. 2011.06.24-2011.06.25 : 久留米
296. Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Chen J, Mizumoto K, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato S, Ohashi Y, Cheng A, Okusaka T: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. American Society of Clinical Oncology 47th Annual Meeting (Abstract #4007), 2011.6.7, Chicago.
297. M.Ueno, S. Ohkawa, Kazuya Sugimori, Satoshi Kobayashi, Taku Kaneko, Masataka Taguri, Satoshi Morita: Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer (YCOG001). 46th ASCO, 2011.6.8, McCormick Place, Chicago
298. M. Ikeda, G. Bodoky, T. Okusaka, S. Ohkawa, A. Fukutomi, A. Swieboda-Sadlej, AF. Sobrero, V. Haddad,

- JS. McGreivy : A phase III trial of ganitumab(GAN, AMG 479) with gemcitabine(G) as first-line treatment(Tx) in patients(pts) with metastatic pancreatic cancer(MPC): An analysis of safety from the GAMMA trial(GEM and AMG479 in Metastatic Adenocarcinoma of the Pancreas). 47thASCO, 2011.6.3, McCormick Place, Chicago
299. Ogura T, Yamao K, Sawaki A, Mizuno N, Hara K, Hijioka S, Niwa Y, Tajika M, Kawai H, Kondo S, Saeki A, Haba S, Hosoda W, Yatabe Y, Bhatia V, Higuchi K : Clinical usefulness of K-ras gene mutation analysis in EUS-FNA specimens from pancreatic mass lesions. Digestive Disease Week, 2011.(Chicago)
300. Hijioka S, Sawaki A, Mizuno N, Hara K,, Haba S, Ogura T, Kondo S, Kawai H, Tajika M, Niwa Y, Yamao K: Role of EUS and EUS-guided FNA for metastasis to pancreas: A Tertiary Center Experience. Digestive Disease Week, 2011.(Chicago)
301. Kondo S, Ueno H, Morizane C, Koizumi F, Tamura K, Okusaka T. The association of long pentraxin 3 on prognosis in pancreatic carcinoma patients on gemcitabine-based chemotherapy. (General Poster Session, Tumor Biology), 2011 ASCO Annual Meeting, June 5-8, 2011, Chicago, IL, U.S.A. J Clin Oncol 29(Suppl): Abstract No.10536, 2011.
302. Ohashi Y, Tanaka M, Boku N, Ueno H, Okusaka T. Quality of life (QOL) evaluation within a randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable, advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. (General Poster Session, Patients and Survivor Care), 2011 ASCO Annual Meeting, June 5-8, 2011, Chicago, IL, U.S.A. J Clin Oncol 29(Suppl): Abstract No.9070, 2011
303. S. Mitsunaga, M. Ikeda, K. Nakachi, I. Ohno, S. Shimizu, H. Takahashi, H. Okuyama, M. Inagaki, J. Furuse, A. Ochiai. Use of elevated IL-1 to predict prognosis in patients with advanced pancreatic cancer with high IL-6 and wasting condition. 2011 ASCO Annual Meeting, June 5-8, 2011, Chicago, IL, U.S.A.
304. 高橋進一郎、木下平、小西大、木下敬弘、後藤田直人、加藤祐一郎 池田公史、仲地耕平. 局所進行膵がん化学療法後の切除例の検討. 第 23 回日本肝胆膵外科学会・学術集会. 2011.6.10 東京
305. 古瀬純司: 膵癌化学療法の最新情報. S-1 のエビデンスとプラクティス. ランチョンセミナー. 第 97 回日本消化器病学会九州支部例会. 第 91 回日本消化器内視鏡学会九州支部例会. 2011.6.25, 久留米市
306. 須藤研太郎, 山口武人, 原太郎, 中村和貴, 傳田忠道, 廣中秀一, 相馬寧, 新井裕之, 多田素久, 太和田勝之, 三方林太郎, 露口利夫, 石原武. 進行膵癌に対する化学放射線療法におけるメタリックステントの安全性に関する検討. 第 92 回日本消化器内視鏡学会関東地方会, 2011.6.11, 東京.
307. 辻江正徳、宮本敦史、中森正二、安井昌義、大宮英泰、池永雅一、平尾素宏、高見康二、藤谷和正、三嶋秀行、辻仲利政. 当院における単孔式腹腔鏡下胆嚢摘出術の検討. 第 23 回日本肝胆膵外科学会・学術集会, 2011.6.8 日, 東京
308. 奥坂拓志. ミニシンポジウム 座長膵癌に対する全身化学療法 第 97 回日本消化器病学会総会 2011.5.13-5.15, 東京都
309. 奥坂拓志. モーニングセミナー (スポンサードセミナー: 中外製薬) 膵癌の薬物治療. 第 97 回日本消化器病学会総会 2011.5.13-5.15, 東京都
310. 上野 誠、小林智、大川伸一、亀田亮、宮川薫: 膵癌化学療法における NLR, CRP の意義. 第 97 回日本消化器病学会総会、2011.5.15、京王プラザホテル、東京
311. 中村聡明. RENAL FUNCTION AFTER PREOPERATIVE CHEMORADIATION FOR T3-PANCREATIC CANCER . ESTRO Anniversary Congress, 2011.5.8, London (UK)
312. Fujimori N, Aso A, Oono T, Kubo H, Itaba S, Igarashi H, Nakamura K, Takayanagi R, Ito T. Usefulness of Endoscopic Ultrasonography in the Diagnosis of Pancreatic Neuroendocrine Tumors. 2011 DIGESTIVE DISEASE WEEK.

May.7-10,2011,Chicago, USA.

313. 光永修一、池田公史、仲地耕平、鈴木雅美、加藤博之、寺尾公男. 膵がんにおける抗 IL-6 療法の意義. 第 84 回日本内分泌学会学術集会. 2011.4.23 神戸市.
314. 奥坂拓志. (2-S-8【シンポジウム】急増する難治癌(膵癌)対策) 切除不能膵癌の化学療法. 第 28 回日本医学会総会 2011 東京 2011.4.8-10,東京都
315. 小川 和彦, 伊藤 芳紀, 唐澤 克之, 小川 芳弘, 大西 洋, 楮本 智子, 澁谷 景子, 渋谷 均, 根本 建二, 西村 恭昌. 膵臓癌に対する放射線治療 JROSG による全国実態調査報告. 第 70 回日本医学放射線学会学術集会. 2011.4.9 日 横浜

#### H. 知的財産権の出願・登録状況(予定を含む。)

1. 特許取得  
なし。
2. 実用新案登録  
なし。
3. その他  
特記すべきことなし。

## Ⅱ. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ueno H, Ioka T, <u>Ikeda M</u> , <u>Ohkawa S</u> , <u>Yanagimoto H</u> , Boku N, <u>Fukutomi A</u> , Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, <u>Furuse J</u> , Funakoshi A, Hatori T, <u>Yamaguchi T</u> , Egawa S, Sato A, Ohhashi Y, <u>Okusaka T</u>	Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study	J Clin Oncol	31(13)	1640-8	2013
<u>Ikeda M</u> , Ioka T, Ito Y, Yonemoto N, Nagase M, Yamao K, Miyakawa H, <u>Ishii H</u> , <u>Furuse J</u> , Sato K, Sato T, <u>Okusaka T</u>	A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer	Int J Radiat Oncol Biol Phys	85(1)	163-9	2013
Sudo K, Ishihara T, Hirata N, Ozawa F, Ohshima T, Azemoto R, Shimura K, Nihei T, Nishino T, Nakagawa A, Nakamura K, Hara T, Tada M, Mikata R, Tawada K, <u>Yokosuka O</u> , Nakaji S, <u>Yamaguchi T</u>	Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer	Cancer Chemother Pharmacol	73(2)	389-96	2014



Ioka T, <u>Katayama K</u> , et al	Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post-marketing surveillance in Japan	Jpn J Clin Oncol	43	139-45	2013
Morizane C, <u>Okusaka T</u> , Ueno H, Kondo S, <u>Ikeda M</u> , <u>Furuse J</u> , Shinichi O, Nakachi K, Mitsunaga S, Kojima Y, Suzuki E, Ueno M, <u>Yamaguchi T</u>	Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients	Cancer Chemother Pharmacol	69(4)	957-64	2012
Ozaka M, Matsumura Y, <u>Ishii H</u> , et al	Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)	Cancer Chemother Pharmacol	69(5)	1197-204	2012
Ogawa K, <u>Ito Y</u> , et al ; Japanese Radiation Oncology Study Group Working Subgroup of Gastrointestinal Cancers	Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival	Int J Radiat Oncol Biol Phys	83	559-65	2012
Ueno H, <u>Okusaka T</u> , <u>Furuse J</u> , Yamao K, Funakoshi A, Boku N, <u>Ohkawa S</u> , <u>Yokosuka O</u> , <u>Tanaka K</u> , Moriyasu F, <u>Nakamori S</u> , Sato T	Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer	Jpn J Clin Oncol	41(8)	953-8	2011
<u>Okusaka T</u> , <u>Furuse J</u> , Funakoshi A, <u>Ito T</u> , Yamao K, <u>Ohkawa S</u> , Boku N, Komatsu Y, <u>Nakamori S</u> , <u>Iguchi H</u> , <u>Ito T</u> , et al	Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer	Cancer Sci	102(2)	425-31	2011
Sudo K, <u>Yamaguchi T</u> , Nakamura K, Denda T, Hara T, Ishihara T, <u>Yokosuka O</u>	Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer	Cancer Chemother Pharmacol	67(2)	249-54	2011

Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Hara T, Denda T, Tawada K, Imagumbai T, Araki H, Sakai M, Hatano K, Kawakami H, Uno T, Ito H, Yokosuka O	Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer	Int J Radiat Oncol Biol Phys	80(1)	119-25	2011
古瀬純司	膵・胆道癌薬物療法：臨床試験を読む！—最新の動向と実地診療へのインパクト—。膵・胆道癌化学療法の動向—臨床試験の読み方	胆と膵	34(8)	593-598	2013
土岐真朗, 古瀬純司, 他	生活習慣と膵疾患。膵癌のリスクファクターとしての糖尿病。効率的な膵癌スクリーニングを目指して	膵臓	27(2)	153-157	2012
原太郎, 山口武人, 他	非切除・化学療法施行例に対してステント治療—抗腫瘍療法を前提とした進行膵癌に対する胆管ステントリング—	胆と膵	34	825-832	2013
須藤研太郎, 横井左奈, 大平美紀, 中村和貴, 原太郎, 瀬座勝志, 傳田忠道, 広中秀一, 三梨桂子, 鈴木拓人, 相馬寧, 北川善康, 喜多絵美里, 中村奈海, 稲垣千晶, 山口武人	切除不能膵癌におけるEUS-FNA検体を用いた網羅的ゲノム解析による個別化治療確立の試み(解説/特集)	胆と膵	34(2)	185-189	2013
須藤研太郎, 山口武人, 他 横須賀收	局所進行膵癌に対する非切除治療の意義(解説/特集)	膵臓	27(5)	656-662	2012
大川伸一	遠隔転移を伴う膵癌に対するFOLFIRINOX療法の第Ⅲ相試験	胆と膵	34(4)	615-618	2013
中森正二, 他	切除不能進行・再発膵癌におけるUFT 先行投与 Gemcitabine 併用化学療法の多施設共同第Ⅱ相臨床試験	癌と化学療法	38(5)	789-792	2011

松本俊彦, 竹治 智, 浅木彰則, 梶原猛史, 仁科智裕, 堀伸一郎, 池田宜央, 灘野成人, 井口東郎	高度肝転移をともなつた膵癌に対するGemcitabine/テガフル・ギメラシル・オテラシルカリウム配合剤(S-1)併用療法の治療成績	日本消化器病学会 雑誌	108	2003- 2009	2011
古川正幸, 他	2型糖尿病に発症する膵癌の臨床的特徴	膵臓	27	145-152	2012
久野晃聖, 藤山隆, 杉本理恵, 奥村幸彦, 古川正幸	GemcitabineおよびS-1に治療抵抗性となつた進行膵がんに対する追加化学療法の有効性	膵臓	28	56-61	2013
中村聡明	膵癌治療における放射線療法の役割と課題	胆と膵	32(4)	319-322	2011

### Ⅲ. 研究成果の刊行物・別刷り

## Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao, Tomotaka Shimamura, Masayuki Sho, Masayuki Kitano, Ann-Lii Cheng, Kazuhiro Mizumoto, Jen-Shi Chen, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Sato, Yasuo Ohashi, Takuji Okusaka, and Masao Tanaka

See accompanying editorial on page 1621

Author affiliations appear at the end of this article.

Published online ahead of print at [www.jco.org](http://www.jco.org) on April 1, 2013.

Written on behalf of the Gemcitabine and S-1 Trial Group.

Supported by Taiho Pharmaceutical and TTY Biopharm.

Presented in part at the 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical trial information: NCT00498225.

Corresponding author: Takuji Okusaka, MD, Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; e-mail: [tokusaka@ncc.go.jp](mailto:tokusaka@ncc.go.jp).

© 2013 by American Society of Clinical Oncology

0732-183X/13/3113w-1640w/\$20.00

DOI: 10.1200/JCO.2012.43.3680

### A B S T R A C T

#### Purpose

The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority of gemcitabine plus S-1 compared with gemcitabine alone with respect to overall survival.

#### Patients and Methods

The participants were chemotherapy-naïve patients with locally advanced or metastatic pancreatic cancer. Patients were randomly assigned to receive only gemcitabine (1,000 mg/m<sup>2</sup> on days 1, 8, and 15 of a 28-day cycle), only S-1 (80, 100, or 120 mg/d according to body-surface area on days 1 through 28 of a 42-day cycle), or gemcitabine plus S-1 (gemcitabine 1,000 mg/m<sup>2</sup> on days 1 and 8 plus S-1 60, 80, or 100 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle).

#### Results

In the total of 834 enrolled patients, median overall survival was 8.8 months in the gemcitabine group, 9.7 months in the S-1 group, and 10.1 months in the gemcitabine plus S-1 group. The noninferiority of S-1 to gemcitabine was demonstrated (hazard ratio, 0.96; 97.5% CI, 0.78 to 1.18;  $P < .001$  for noninferiority), whereas the superiority of gemcitabine plus S-1 was not (hazard ratio, 0.88; 97.5% CI, 0.71 to 1.08;  $P = .15$ ). All treatments were generally well tolerated, although hematologic and GI toxicities were more severe in the gemcitabine plus S-1 group than in the gemcitabine group.

#### Conclusion

Monotherapy with S-1 demonstrated noninferiority to gemcitabine in overall survival with good tolerability and presents a convenient oral alternative for locally advanced and metastatic pancreatic cancer.

*J Clin Oncol* 31:1640-1648. © 2013 by American Society of Clinical Oncology

### INTRODUCTION

Pancreatic cancer (PC) is currently the eighth leading cause of cancer-related mortality worldwide, with an estimated 266,000 deaths in 2008.<sup>1</sup> Gemcitabine became the standard treatment for advanced PC, improving overall survival (OS) compared with fluorouracil.<sup>2</sup> Although various gemcitabine-based combination regimens have been evaluated, only erlotinib added to gemcitabine showed a survival benefit over gemcitabine, and that was marginal.<sup>3</sup>

Fluorouracil/leucovorin plus irinotecan plus oxaliplatin (FOLFIRINOX), a gemcitabine-free combination regimen, has recently demonstrated a clear survival benefit compared with gemcitabine for patients with metastatic PC who have a performance status of 0 to 1.<sup>4</sup> However, because FOLFIRINOX is associated with significant toxicity, this regimen must be limited to patients with good performance status and requires close monitoring.<sup>5</sup>

In Japan, clinical trials of S-1 (TS-1; Taiho Pharmaceutical, Tokyo, Japan) have been conducted since the early 2000s for patients with PC. S-1

is an oral fluoropyrimidine derivative shown to be effective for gastric and various other types of cancers.<sup>6,7</sup> Phase II studies of S-1 as first-line therapy for metastatic PC resulted in good response rates of 21.1% to 37.5%.<sup>8,9</sup> Consequently, S-1 was approved for the indication of PC in Japan in 2006. Development of gemcitabine plus S-1 (GS) studies have also been initiated, mainly in Japan, and two phase II studies reported high response rates of 44.4% to 48.5% and good median OS of 10.1 to 12.5 months.<sup>10,11</sup>

Because S-1 and GS have shown promising activity in PC, the present randomized phase III study (GEST [Gemcitabine and S-1 Trial] study) was designed to evaluate whether S-1 alone is noninferior to gemcitabine and whether GS is superior to gemcitabine alone for locally advanced and metastatic PC with respect to OS.

PATIENTS AND METHODS

Study Design

This randomized phase III study, sponsored by Taiho Pharmaceutical in Japan and TTY Biopharm in Taiwan, was conducted as a postmarketing study in Japan and as a registration study in Taiwan and was in compliance with the Declaration of Helsinki. Data were collected by a contract research organization contracted by the sponsors and were analyzed by a bio-statistician (Y.O.). An independent data and safety monitoring committee reviewed efficacy and safety data. The study was approved by the ethics committee or institutional review board of each participating center.

Patients

All patients provided written informed consent. Enrollment criteria were locally advanced or metastatic PC, histologically or cytologically proven diagnosis of adenocarcinoma or adenosquamous carcinoma, no prior chemotherapy or radiotherapy for PC, age of more than 20 years (the protocol was amended to restrict the eligible age to < 80 years after four of the first eight patients who were ≥ 80 years experienced serious adverse events), an Eastern Cooperative Oncology Group performance status score of 0 to 1, and adequate organ functions (see Appendix, online only).

Treatment

Random assignment was performed centrally with stratification by extent of disease (locally advanced disease v metastatic disease) and institution

using the minimization method. Patients allocated to gemcitabine alone received gemcitabine at a dose of 1,000 mg/m<sup>2</sup> intravenously over 30 minutes on days 1, 8, and 15 of a 28-day cycle. Patients allocated to S-1 alone received S-1 orally twice daily at a dose according to the body-surface area (BSA) (< 1.25 m<sup>2</sup>, 80 mg/d; ≥ 1.25 to < 1.5 m<sup>2</sup>, 100 mg/d; ≥ 1.5 m<sup>2</sup>, 120 mg/d) on days 1 through 28 of a 42-day cycle. Patients allocated to GS received gemcitabine at a dose of 1,000 mg/m<sup>2</sup> on days 1 and 8 plus S-1 orally twice daily at a dose according to the BSA (< 1.25 m<sup>2</sup>, 60 mg/d; ≥ 1.25 to < 1.5 m<sup>2</sup>, 80 mg/d; ≥ 1.5 m<sup>2</sup>, 100 mg/d) on days 1 through 14 of a 21-day cycle. The dose levels of S-1 used in the GS group were based on the results of a previous phase II study of GS, in which 1,000 mg/m<sup>2</sup> of gemcitabine was combined with 120 mg/d, 100 mg/d, and 80 mg/d of S-1. In that study, the rate of treatment withdrawal due to adverse events was 41% (22 of 54 patients), the rate of grade 3 or worse neutropenia was 80%, and the dose was reduced in 56% of the patients (30 of 54 patients).<sup>11</sup> Consequently, 20 mg/d lower doses of S-1 than those used in the S-1 monotherapy group were used in the GS group in the present study.

In the event of predefined toxic events, protocol-specified treatment modifications were permitted (see Appendix).

Assessments

Physical examinations, CBCs, and biochemistry tests were usually checked at 2-week intervals in the S-1 group and at each time of administration of gemcitabine both in the gemcitabine group and in the GS group. All adverse events were assessed according to the Common Terminology Criteria for Adverse Events, version 3.0. Computed tomography or magnetic resonance imaging was performed every 6 weeks until disease progression, and response was assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0.<sup>12</sup> Quality of life was assessed using the EuroQol 5 Dimension questionnaire<sup>13</sup> at baseline and 6, 12, 24, 48, and 72 weeks after the study treatment had begun.

Statistical Analysis

The primary end point was OS, defined as time from date of random assignment to date of death from any cause. Secondary end points were progression-free survival (PFS), objective response rate, safety, and quality of life. PFS was counted from the date of random assignment to the date of death without progression or of progression as confirmed by the investigator's assessment. The median OS was assumed to be 7.5 months in the gemcitabine group, 8.0 months in the S-1 group, and 10.5 months in the GS group. To maintain a one-sided significance level of .025 for the entire study while testing two hypotheses (ie, noninferiority and superiority), the one-sided significance




Fig 1. CONSORT diagram. GS, gemcitabine plus S-1.

level for each comparison was set at .0125. The statistical considerations are detailed in the Appendix.

The superiority of GS was evaluated by the stratified log-rank test. To assess the noninferiority of S-1, we used the Cox proportional hazards model to calculate two-sided, 97.5% CIs of the hazard ratio (HR). The noninferiority margin of S-1 was set at 1.33; that is, the null hypothesis was that the median OS with S-1 would be approximately 2 months shorter than with gemcitabine. We decided this setting was justified considering the convenience of S-1 and because there are few effective drugs for the disease. Furthermore, to interpret the obtained data, the Bayesian analysis of the log HR on the basis of the noninformative prior distribution was preplanned. Posterior probability with log HR within a stricter threshold (log 1.15) was also calculated.<sup>14</sup>

In each assigned group, the time-to-event distribution was estimated with the Kaplan-Meier method. The 95% CI of the median survival time was calculated by the method of Brookmeyer and Crowley.<sup>15</sup> In addition, the Greenwood formula<sup>16</sup> was used to calculate the 95% CI for survival rates. In subgroup analyses, interaction tests were performed to assess the homogeneity of the effect of treatment on OS.

The primary end point was analyzed for the full analysis set. All *P* value evaluations were two-tailed. Data analyses were done with SAS, version 9.1.3 (SAS Institute, Cary, NC).

## RESULTS

### Patients

Between July 2007 and October 2009, a total of 834 patients were enrolled from 75 institutions in Japan and Taiwan (768 in Japan and 66 in Taiwan). Two patients in the GS group were excluded from the study because enrollment was conducted before obtaining written informed consent. The remaining 832 patients were included in the full analysis set and used to calculate OS and PFS (Fig 1). The three treatment groups were well balanced with respect to demographic and baseline characteristics (Table 1).

### Study Treatment

The median duration of treatment was 2.6 months in the gemcitabine group, 2.6 months in the S-1 group, and 4.3 months in the GS group. The main reasons for treatment discontinuation were either disease progression (202 patients [72.9%] in the gemcitabine group,

**Table 1.** Demographics and Baseline Characteristics of Patients (full-analysis set population)

Characteristic	Gemcitabine (n = 277)		S-1 (n = 280)		GS (n = 275)		Total (N = 832)	
	No.	%	No.	%	No.	%	No.	%
Sex								
Male	170	61.4	170	60.7	158	57.5	498	59.9
Female	107	38.6	110	39.3	117	42.5	334	40.1
Age, years								
< 65	134	48.4	145	51.8	137	49.8	416	50.0
≥ 65	143	51.6	135	48.2	138	50.2	416	50.0
ECOG PS								
0	181	65.3	178	63.6	172	62.5	531	63.8
1	96	34.7	102	36.4	103	37.5	301	36.2
Extent of disease								
Locally advanced	66	23.8	68	24.3	68	24.7	202	24.3
Metastatic	211	76.2	212	75.7	207	75.3	630	75.7
Type of tumor								
Adenocarcinoma	272	98.2	276	98.6	272	98.9	820	98.6
Adenosquamous carcinoma	5	1.8	4	1.4	3	1.1	12	1.4
Pancreas excision								
No	254	91.7	264	94.3	248	90.2	766	92.1
Yes	23	8.3	16	5.7	27	9.8	66	7.9
Tumor location*								
Head	122	44.0	110	39.3	116	42.2	348	41.8
Body	88	31.8	124	44.3	102	37.1	314	37.7
Tail	68	24.5	55	19.6	66	24.0	189	22.7
Biliary drainage								
No	202	72.9	217	77.5	209	76.0	628	75.5
Yes	75	27.1	63	22.5	66	24.0	204	24.5
CEA, ng/mL								
Median	5.7		5.6		5.9		5.7	
IQR	3.0-20.1		2.5-18.4		2.5-20.7		2.6-19.5	
CA19-9, U/mL								
Median	1,044		726		441		712	
IQR	52-5,002		64-5,000		45-5,090		55-5,002	
CRP, mg/dL								
Median	0.40		0.50		0.40		0.43	
IQR	0.11-1.38		0.18-1.57		0.15-1.60		0.15-1.57	

Abbreviations: CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; GS, gemcitabine plus S-1; IQR, interquartile range.

\*Including patients with tumors involving multiple sites.

215 [76.8%] in the S-1 group, and 162 [58.9%] in the GS group) or adverse events (40 patients [14.4%] in the gemcitabine group, 38 [13.6%] in the S-1 group, and 76 [27.6%] in the GS group). The median relative dose-intensity was 83.0% in the gemcitabine group, 96.1% in the S-1 group, and 83.3% for gemcitabine and 87.4% for S-1 in the GS group.

**Survival**

The median duration of follow-up for surviving patients was 18.4 months (range, 0.3 to 36.9 months) as of July 31, 2010. The analysis of OS was based on 710 deaths (85.3%) among the 832 patients. The median OS was 8.8 months (95% CI, 8.0 to 9.7) in the gemcitabine group, 9.7 months (95% CI, 7.6 to 10.8) in the S-1 group, and 10.1 months (95% CI, 9.0 to 11.2) in the GS group (Fig 2A). OS rates at 12 and 24 months were respectively 35.4% and 9.2% in the gemcitabine group, 38.7% and 12.7% in the S-1 group, and 40.7% and 14.5% in the GS group. The noninferiority of S-1 to gemcitabine with respect to OS was demonstrated (HR, 0.96; 97.5% CI, 0.78 to 1.18;  $P < .001$  for

noninferiority). The Bayesian posterior probability that the HR of S-1 relative to gemcitabine would be less than 1.15 was calculated to be 98% on the basis of the noninformative prior distribution. However, GS failed to improve OS at a statistically significant level as compared with gemcitabine (HR, 0.88; 97.5% CI, 0.71 to 1.08;  $P = .15$ ).

The analysis of PFS was based on 793 events (95.3%) among the 832 patients. The median PFS was 4.1 months (95% CI, 3.0 to 4.4) in the gemcitabine group, 3.8 months (95% CI, 2.9 to 4.2) in the S-1 group, and 5.7 months (95% CI, 5.4 to 6.7) in the GS group (Fig 2B). PFS rates at 6 and 12 months were respectively 29.8% and 9.1% in the gemcitabine group, 26.9% and 7.2% in the S-1 group, and 20.3% and 2.3% in the GS group. S-1 was shown to be noninferior to gemcitabine with respect to PFS (HR, 1.09; 97.5% CI, 0.90 to 1.33;  $P = .02$  for noninferiority), and GS significantly improved PFS compared with gemcitabine (HR, 0.66; 97.5% CI, 0.54 to 0.81;  $P < .001$ ).

Subgroup analyses of survival according to pretreatment characteristics showed no significant interaction between S-1 and gemcitabine in any subgroup (Fig 3A). However, GS showed a favorable HR compared with gemcitabine in the subsets of patients with locally advanced disease or patients with a performance status of 1 (Fig 3B).

**Response to Therapy**

The objective response rate was 13.3% (95% CI, 9.3 to 18.2) in the gemcitabine group, 21.0% (95% CI, 16.1 to 26.6) in the S-1 group, and 29.3% (95% CI, 23.7 to 35.5) in the GS group (Table 2). The objective response rate was significantly higher in the S-1 group ( $P = .02$ ) and in the GS group ( $P < .001$ ) than in the gemcitabine group.


**Second-Line Chemotherapy**

Second-line chemotherapy was performed in 184 patients (66.4%) in the gemcitabine group, 185 (66.1%) in the S-1 group, and 172 (62.5%) in the GS group. In the gemcitabine group, 140 patients (50.5%) received S-1 alone or S-1–based regimens, and in the S-1 group 162 (57.9%) received gemcitabine alone or gemcitabine-based regimens as second-line chemotherapy. The most common second-line regimens in the GS group were gemcitabine alone (61 patients), GS (53 patients), S-1 alone (24 patients), irinotecan (six patients), and fluorouracil/leucovorin plus oxaliplatin (four patients). In Japan and Taiwan, the use of treatments such as erlotinib, oxaliplatin, and irinotecan for PC was not approved at the time of this study; hence gemcitabine, S-1, or both were used in most patients as second-line chemotherapy.

**Adverse Events and Quality-Adjusted Life-Years**


The major grade 3 or worse adverse events are listed in Table 3. Patients in the gemcitabine group had significantly higher incidences of grade 3 or worse leukopenia, neutropenia, thrombocytopenia, elevated AST levels, and elevated ALT levels as compared with patients in the S-1 group. However, the incidence of grade 3 or worse diarrhea was higher in the S-1 group than in the gemcitabine group. Patients in the GS group had significantly higher incidences of grade 3 or worse leukopenia, neutropenia, thrombocytopenia, rash, diarrhea, vomiting, and stomatitis than patients in the gemcitabine group.

There were three deaths considered possibly related to the protocol treatment (interstitial lung disease, sepsis, and acute hepatitis B) in the gemcitabine group, one in the S-1 group (unknown cause), and



**Fig 2.** Kaplan-Meier estimates of (A) overall survival and (B) progression-free survival according to treatment group. GS, gemcitabine plus S-1.





**Fig 3.** Forest plots of treatment effects on overall survival in subgroup analyses. Forest plots show effects on overall survival of patients in each subgroup. (A) S-1; (B) gemcitabine plus S-1 (GS). Each blue circle shows the treatment response. ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.

four in the GS group (unknown cause associated with myelosuppression, cerebral infarction, cerebrovascular disorder, and interstitial lung disease). The results of quality-adjusted life-years (QALYs) are in the Appendix and the details of quality-of-life assessments will be reported elsewhere.

### DISCUSSION

The overall and PFS curves in the S-1 group were nearly identical to those in the gemcitabine group, confirming the noninferiority of S-1

to gemcitabine in terms of OS and PFS (Fig 2A, 2B). Toxicity profiles of these two drugs differed slightly: gemcitabine tended to show hematologic toxicity, whereas S-1 tended to show GI toxicity. However, both S-1 and gemcitabine were generally well tolerated. Furthermore, the results of QALY evaluation demonstrated that S-1 and gemcitabine were equivalent. Hence our results suggest that S-1 can be used as first-line therapy as a convenient oral alternative for locally advanced and metastatic PC. To the best of our knowledge, this is the first phase III study to demonstrate the noninferiority of a single anticancer agent to gemcitabine alone for locally advanced and metastatic PC.

GS or S-1 v Gemcitabine for Pancreatic Cancer

**Table 2.** Objective Response Rates (patients with measurable lesions)

Variable	Gemcitabine (n = 241)		S-1 (n = 248)		GS (n = 242)		<i>P</i> ( $\chi^2$ test)	
	No.	%	No.	%	No.	%	Gemcitabine v S-1	Gemcitabine v GS
<b>Response</b>								
Complete response	1	0.4	0	0	2	0.8		
Partial response	31	12.9	52	21.0	69	28.5		
Stable disease	119	49.4	105	42.3	102	42.1		
Progressive disease	75	31.1	69	27.8	37	15.3		
Objective response rate*	32	13.3	52	21.0	71	29.3	.02	< .001
95% CI	9.3 to 18.2		16.1 to 26.6		23.7 to 35.5			
Disease control rate†	151	62.7	157	63.3	173	71.5	.88	.04
95% CI	56.2 to 68.8		57.0 to 69.3		65.4 to 77.1			

Abbreviation: GS, gemcitabine plus S-1.

\*The objective response rate was defined as the proportion of patients who had a complete response or partial response.

†The disease control rate was defined as the proportion of patients who had a complete response, partial response, or stable disease.

At the time of planning this study, the participants of nearly all phase III trials included both patients with locally advanced as well as those with metastatic PC. However, because locally advanced and metastatic diseases are two clinical entities, it is recently recommended that patients with locally advanced disease should be studied separately from those with metastatic disease.<sup>17</sup> Although this study included locally advanced disease, subgroup analysis of extent of disease showed no significant interaction between S-1 and gemcitabine (Fig 3A). Moreover, the OS curve in the S-1 group was still similar to those in the gemcitabine group in both locally advanced and metastatic disease (Fig 4A, 4B). Regarding pathologic diagnosis, our study included adenocarcinoma, although its percentage was very low (1.4% of whole population). When the data were reanalyzed after

excluding patients with adenosquamous carcinoma, the results for OS for gemcitabine versus S-1 was unchanged (HR, 0.96; 95% CI, 0.81 to 1.15). The selection of one treatment over the other will depend primarily on patient preference, clinical factors, or drug costs, as biomarkers indicating effective use of S-1 or gemcitabine do not exist at this time.


Regarding GS, the OS did not differ significantly from gemcitabine, although the PFS was significantly longer in the GS group. Second-line chemotherapy mainly with S-1 in the gemcitabine group may be one reason for this discrepancy. The median OS in the gemcitabine group was 8.8 months, which is longer than those previously reported for gemcitabine in other phase III studies for locally advanced and metastatic PC.<sup>2,3,18-24</sup> Although the efficacy of second-line

**Table 3.** Grade 3 or Worse Adverse Events (safety population)

Event	Gemcitabine (n = 273)		S-1 (n = 272)		GS (n = 267)		<i>P</i> (Fisher's exact test)	
	No.	%	No.	%	No.	%	Gemcitabine v S-1	Gemcitabine v GS
<b>Hematologic</b>								
Leukocytes	51	18.7	10	3.7	101	37.8	< .001	< .001
Neutrophils	112	41.0	24	8.8	166	62.2	< .001	< .001
Platelets	30	11.0	4	1.5	46	17.2	< .001	.05
Hemoglobin	39	14.3	26	9.6	46	17.2	.11	.41
<b>Nonhematologic</b>								
ALT	41	15.0	16	5.9	29	10.9	< .001	.16
AST	41	15.0	21	7.7	32	12.0	.01	.32
Bilirubin	26	9.5	39	14.3	23	8.6	.09	.77
Fatigue	10	3.7	18	6.6	13	4.9	.13	.53
Rash	2	0.7	2	0.7	11	4.1	1.00	.01
Anorexia	20	7.3	31	11.4	25	9.4	.11	.44
Diarrhea	3	1.1	15	5.5	12	4.5	.004	.02
Mucositis/stomatitis	0	0.0	2	0.7	6	2.2	.25	.01
Nausea	5	1.8	5	1.8	12	4.5	1.00	.09
Vomiting	2	0.7	4	1.5	12	4.5	.45	.006
Febrile neutropenia	1	0.4	1	0.4	5	1.9	1.00	.12
Infection with normal ANC	6	2.2	7	2.6	6	2.2	.79	1.00
Pneumonitis	5	1.8	0	0.0	2	0.7	.06	.45

NOTE. Grades of adverse events were defined according to the Common Terminology Criteria for Adverse Events (version 3.0).

Abbreviations: ANC, absolute neutrophil count; GS, gemcitabine plus S-1.



**Fig 4.** Kaplan-Meier estimates of overall survival in (A) locally advanced disease and (B) metastatic disease. GS, gemcitabine plus S-1.

therapy was not analyzed in this study, a phase II study of second-line S-1 in patients with gemcitabine-refractory PC showed a 15% response rate and 58% disease control rate.<sup>25</sup> Compared with the GS group, which had no promising second-line therapy, the use of S-1 as second-line therapy in the gemcitabine group might have contributed to prolonged survival.

The lack of a significant difference in OS between gemcitabine and GS suggests that gemcitabine and S-1 could be used sequentially rather than concurrently. However, the GS group showed a high response rate and favorable PFS, with a better HR of 0.66 compared with other gemcitabine-based combination regimens in other phase III studies (HR = 0.75 to 1.07).<sup>3,18,20,22,24</sup> Furthermore, the GS group showed a favorable HR for OS in patients with locally advanced disease or patients with a performance status of 1 in the subgroup analyses. Therefore, it is speculated that there may be room to select GS therapy, depending on the profile of the patients and further investigations.

Regarding oral fluoropyrimidines other than S-1, capecitabine has been studied in patients with PC, mainly in the West. In two phase

III studies, a combination of gemcitabine plus capecitabine did not significantly prolong survival as compared with gemcitabine alone.<sup>19,20</sup> The results of a meta-analysis of these phase III studies, however, demonstrated that survival was significantly prolonged by combined treatment, with an HR of 0.86,<sup>20</sup> which is similar to the HR for GS in the present study (0.88).

One limitation of our study is that it is uncertain whether our results can be simply extrapolated to Western patients because pharmacokinetics and pharmacodynamics of S-1 between Westerners and East Asians may be different.<sup>26,27</sup> Although S-1 is available for PC only in Japan at the moment, if S-1 is used in Western patients, its effectiveness should be monitored and the dose should be carefully adjusted accordingly. Another potential limitation is that the protocol-specified noninferiority margin of 1.33 may be large. However, the result of point estimate of the HR of S-1 was 0.96 and actual upper limit of the 97.5% CI was 1.18, which was sufficiently lower than the prespecified margin of 1.33. Furthermore, Bayesian posterior probability with log HR within a stricter threshold (log 1.15) was 98%.

Given that most gemcitabine-based combination regimens have not been shown to be significantly superior to gemcitabine alone and that FOLFIRINOX has demonstrated overwhelming superiority to gemcitabine in a phase III study, reporting an HR of 0.57,<sup>4</sup> the development of gemcitabine-free combination regimens for first-line treatment seems to be warranted. However, because FOLFIRINOX requires the placement of a central venous access port for continuous intravenous infusion of fluorouracil, it can be expected that S-1, an oral fluoropyrimidine, will replace the continuous infusion of fluorouracil in the future.

In conclusion, this study has verified the noninferiority of S-1 to gemcitabine, thereby suggesting that S-1 can be used as first-line therapy for locally advanced and metastatic PC. Because S-1 was confirmed to be a key treatment for PC, S-1-based regimens are expected to be developed in the future to improve the management of this formidable disease.

#### AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

**Employment or Leadership Position:** None **Consultant or Advisory Role:** Hideki Ueno, Taiho Pharmaceutical (C); Tatsuya Ioka, Taiho Pharmaceutical (U); Shinichi Ohkawa, Taiho Pharmaceutical (C); Narikazu Boku, Taiho Pharmaceutical (U); Kenji Yamao, Taiho Pharmaceutical (C); Ann-Lii Cheng, Boehringer Ingelheim (C), sanofi-aventis (C), TTY Biopharm (C); Kazuhiro Mizumoto, Taiho Pharmaceutical (C); Jen-Shi Chen, TTY Biopharm (C); Junji Furuse, Bayer (C), GlaxoSmithKline (C), Kowa (C), Novartis (C), Taiho Pharmaceutical (C); Akihiro Funakoshi, Taiho Pharmaceutical (C); Takashi Hatori, Taiho Pharmaceutical (C); Taketo Yamaguchi, Taiho Pharmaceutical (C); Atsushi Sato, Taiho Pharmaceutical (C); Yasuo Ohashi, Taiho Pharmaceutical (C); Takuji Okusaka, Taiho Pharmaceutical (C); Masao Tanaka, Taiho Pharmaceutical (C) **Stock**

**Ownership:** None **Honoraria:** Hideki Ueno, Taiho Pharmaceutical, Eli Lilly; Tatsuya Ioka, Taiho Pharmaceutical; Masafumi Ikeda, Taiho Pharmaceutical; Shinichi Ohkawa, Taiho Pharmaceutical, Eli Lilly; Chugai; Hiroaki Yanagimoto, Taiho Pharmaceutical; Narikazu Boku, Taiho Pharmaceutical; Akira Fukutomi, Taiho Pharmaceutical, Eli Lilly; Kazuya Sugimori, Taiho Pharmaceutical; Hideo Baba, Taiho Pharmaceutical; Kenji Yamao, Taiho Pharmaceutical, Eli Lilly; Masayuki Sho, Taiho Pharmaceutical; Jen-Shi Chen, TTY Biopharm; Junji Furuse, Taiho Pharmaceutical, Bayer, Eli Lilly; Akihiro Funakoshi, Taiho Pharmaceutical; Atsushi Sato, Taiho Pharmaceutical; Yasuo Ohashi, Taiho Pharmaceutical; Takuji Okusaka, Taiho Pharmaceutical, Eli Lilly; Masao Tanaka, Taiho Pharmaceutical **Research Funding:** Hideki Ueno, Taiho Pharmaceutical; Tatsuya Ioka, Taiho Pharmaceutical; Masafumi Ikeda, Taiho Pharmaceutical; Shinichi Ohkawa, Taiho Pharmaceutical, Eli Lilly; Chugai, Oncotherapy Science, Yakult, Abbott, Amgen; Hiroaki Yanagimoto, Taiho Pharmaceutical; Narikazu Boku, Taiho Pharmaceutical Co. Ltd; Akira Fukutomi, Taiho Pharmaceutical, Eli Lilly; Kazuya Sugimori, Taiho Pharmaceutical; Hideo Baba, Taiho Pharmaceutical; Kenji Yamao, Taiho Pharmaceutical; Tomotaka Shimamura, Taiho Pharmaceutical; Masayuki Sho, Taiho Pharmaceutical; Masayuki Kitano, Taiho Pharmaceutical; Ann-Lii Cheng, TTY Biopharm; Kazuhiro Mizumoto, Taiho Pharmaceutical; Jen-Shi Chen, TTY Biopharm; Junji Furuse, Taiho Pharmaceutical, Bayer, Pfizer, Yakult; Akihiro Funakoshi, Taiho Pharmaceutical; Takashi Hatori, Taiho Pharmaceutical; Taketo Yamaguchi, Taiho Pharmaceutical; Yasuo Ohashi, Taiho Pharmaceutical; Takuji Okusaka,

Taiho Pharmaceutical, Eli Lilly; Masao Tanaka, Taiho Pharmaceutical, Eli Lilly **Expert Testimony:** None **Other Remuneration:** None

#### AUTHOR CONTRIBUTIONS

**Conception and design:** Hideki Ueno, Tatsuya Ioka, Shinichi Ohkawa, Narikazu Boku, Kenji Yamao, Kazuhiro Mizumoto, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Sato, Yasuo Ohashi, Takuji Okusaka, Masao Tanaka  
**Provision of study materials or patients:** Masayuki Kitano, Masao Tanaka  
**Collection and assembly of data:** Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao, Tomotaka Shimamura, Masayuki Sho, Masayuki Kitano, Ann-Lii Cheng, Kazuhiro Mizumoto, Jen-Shi Chen, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Takuji Okusaka, Masao Tanaka  
**Data analysis and interpretation:** Hideki Ueno, Tatsuya Ioka, Shinichi Ohkawa, Narikazu Boku, Kenji Yamao, Kazuhiro Mizumoto, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Sato, Yasuo Ohashi, Takuji Okusaka, Masao Tanaka  
**Manuscript writing:** All authors  
**Final approval of manuscript:** All authors

#### REFERENCES

- Jemal A, Bray F, Center MM, et al: Global cancer statistics. *CA Cancer J Clin* 61:69-90, 2011
- Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. *J Clin Oncol* 15:2403-2413, 1997
- Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 25:1960-1966, 2007
- Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 364:1817-1825, 2011
- Saif MW, Chabot J: Chemotherapy: Metastatic pancreatic cancer—Is FOLFIRINOX the new standard? *Nat Rev Clin Oncol* 8:452-453, 2011
- Saif MW, Syrigos KN, Katirtzoglou NA: S-1: A promising new oral fluoropyrimidine derivative. *Expert Opin Investig Drugs* 18:335-348, 2009
- Shirasaka T: Development history and concept of an oral anticancer agent S-1 (TS-1): Its clinical usefulness and future vistas. *Jpn J Clin Oncol* 39:2-15, 2009
- Ueno H, Okusaka T, Ikeda M, et al: An early phase II study of S-1 in patients with metastatic pancreatic cancer. *Oncology* 68:171-178, 2005
- Okusaka T, Funakoshi A, Furuse J, et al: A late phase II study of S-1 for metastatic pancreatic cancer. *Cancer Chemother Pharmacol* 61:615-621, 2008
- Nakamura K, Yamaguchi T, Ishihara T, et al: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. *Br J Cancer* 94:1575-1579, 2006
- Ueno H, Okusaka T, Furuse J, et al: Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. *Jpn J Clin Oncol* 41:953-958, 2011
- Therasse P, Arbuuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92:205-216, 2000
- EuroQol: A new facility for the measurement of health-related quality of life—The EuroQol Group. *Health Policy* 16:199-208, 1990
- Spiegelhalter DJ, Freedman LS, Parmar MKB: Bayesian approaches to randomized trials. *J R Stat Soc* 157:357-387, 1994
- Brookmeyer R, Crowley J: A confidence interval for the median survival time. *Biometrics* 38:29-41, 1982
- Kalbfleisch JD, Prentice RL: *The Statistical Analysis of Failure Time Data*. New York, NY, Wiley, 1980, p. 14
- Philip PA, Mooney M, Jaffe D, et al: Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. *J Clin Oncol* 27:5660-5669, 2009
- Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. *J Clin Oncol* 24:3946-3952, 2006
- Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Res and the Central European Cooperative Oncology Group. *J Clin Oncol* 25:2212-2217, 2007
- Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. *J Clin Oncol* 27:5513-5518, 2009
- Poplin E, Feng Y, Berlin J, et al: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group. *J Clin Oncol* 27:3778-3785, 2009
- Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. *J Clin Oncol* 28:3605-3610, 2010
- Kindler HL, Niedzwiecki D, Hollis D, et al: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). *J Clin Oncol* 28:3617-3622, 2010
- Kindler HL, Ioka T, Richel DJ, et al: Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomized phase 3 study. *Lancet Oncol* 12:256-262, 2011
- Morizane C, Okusaka T, Furuse J, et al: A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. *Cancer Chemother Pharmacol* 63:313-319, 2009
- Haller DG, Cassidy J, Clarke SJ, et al: Potential regional differences for the tolerability profiles of fluoropyrimidines. *J Clin Oncol* 26:2118-2123, 2008
- Chuah B, Goh BC, Lee SC, et al: Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. *Cancer Sci* 102:478-483, 2011

#### Affiliations

Hideki Ueno and Takuji Okusaka, National Cancer Center Hospital; Junji Furuse, Kyorin University; Takashi Hatori, Tokyo Women's Medical University; Atsushi Sato, Showa University Hospital; Yasuo Ohashi, The University of Tokyo, Tokyo; Tatsuya Ioka, Osaka Medical